Bristol-myers Squibb Compnay

The Dupont Merck Pharmaceutical Company

Syngene International Limited

Dupont Pharmaceuticals Company

Innate Tumor Immunity, Inc.

Flexus Biosciences, Inc.

Steven P Seitz

Jay A Markwalder

James Aaron Balog

David K Williams

Audris Huang

Weifang Shan

Susheel Jethanand Nara

Emily Charlotte Cherney

Saumya Roy

Ashvinikumar V Gavai

Srinivas Cheruku

Srinivasan Thangathirupathy

Soodamani Thangavel

Robert J Cherney

Ramesh Kumar Sistla

Weiwei Guo

Nagalakshmi Pulicharla

Liping Zhang

Yadagiri Kanyaboina

Jay Patrick Powers

Natesan Murugesan

Michael J Orwat

Juan Carlos Jaen

Scott Hunter Watterson

Derek J Norris

Liqi He

Hunter Paul Shunatona

Maureen Kay Reilly

Mikhail Zibinsky

Maksim Osipov

Christine M Tarby

Hilary Plake Beck

Ashok Vinayak Purandare

Jung-Hui Sun

James Ross Walker

Amy C Hart

Daniel O'Malley

Hua Gong

Libing Chen

Robert F Kaltenbach

Gregory James Pacofsky

Susan R Sherk

Sunil Kumar Mandal

Arthur D Patten

Emeka A Akamike

Katerina Leftheris

Jeffrey A Robl

Chunhong He

Shomir Ghosh

Stephen T Wrobleski

Soong-Hoon Kim

Brian E Fink

Wayne D Vaccaro

Kyoung S Kim

Soo Sung Ko

Yan Shi

John S Tokarski

William R Roush

Prasanna Sivaprakasam

Yong Zhang

Philip D Stein

Mona Patel

David J Carini

Shuqun Lin

Patrice Gill

Tai-An Lin

Anthony J Cocuzza

Xiao Zhu

Shefali Srivastava

Vijay T Ahuja

Andrew Forrest Donnell

Rodney Lawrence Parsons, Jr

Jennifer Inghrim

Matthias Broekema

Murugaiah Andappan Murugaiah Subbaiah

Bin Chen

Robert Frank Kaltenbach, Iii

Abdul Ezaz Mutlib

David Donald Christ

Michael Wichroski

Jay Andrew Markwalder

Julian C Lo

Mohini Rajasagi

Jennifer Donnell

The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

NLRP3 modulators

The present invention provides compounds of Formula (I), (II) or (III): (I), (II), (III), wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

The present invention provides compounds of formula (I) wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.

Inhibitors of indoleamine 2,3-dioxygenase and methods of their use

The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

The invention relates generally to compounds that are Mer-Ax1 inhibitors, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

Uracil derivatives as Mer-AXL inhibitors

The present invention provides a compound of formula (II): an inhibitor of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases. Its prodrugs are disclosed. 

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the disclosure.

The present invention provides compounds of formula (I): wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases. 

There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention. 

Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer

Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

Immunoregulatory agents

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

IDO inhibitors

There are disclosed compounds of Formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-di-oxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention. 

There are disclosed compounds that are inhibitors of EZH2, pharmaceutical compositions containing said compounds and methods of treating hyperproliferative, inflammatory, infectious, and immunoregulatory disorders and diseases utilizing the compounds of the invention.

Inhibitors of lysine methyl transferase

Growing community of inventors

Swarthmore, PA, United States of America

Steven P Seitz